Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | See Remarks | September 16, 2026 | September 18, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, General Counsel | September 04, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,508 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 3,674 · Balance 112,508 F1: The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
HALOZYME THERAPEUTICS, INC.
Report date September 04, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,049 |
Ending reported balance
After 2021-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-09-04 · Exercise / conversion · Acquired 6,883 · Balance 23,461 Row 2 · 2021-09-04 · Tax withholding · Disposed 3,412 · Balance 20,049 F1: The reported disposition of 3,412 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,883 |
Reported balance
After 2021-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-04 · Exercise / conversion · Disposed 6,883 · Balance 6,883 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 3,412 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 20:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,674 | $25.00 | $91,853.31 |
DisclosureSEC source: 0001628280-26-062732 · wk-form4_1789762641.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,508 F1 · kind: The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 23:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,989 | $25.03 | $249,985.71 |
DisclosureSEC source: 0001628280-26-061444 · wk-form4_1789082678.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,182 F1 · kind: The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,230 | $26.12 | $32,123.66 |
DisclosureSEC source: 0001628280-26-053754 · wk-form4_1785980535.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,171 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 712 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 884 | $23.61 | $20,871.77 |
DisclosureSEC source: 0001798679-26-000002 · wk-form4_1778110801.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,689 F4 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:40 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,372 | $23.27 | $171,543.49 |
DisclosureSEC source: 0001798679-26-000002 · wk-form4_1778110801.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,573 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.1167 to $23.48, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Due to a scrivener's error on the Reporting Person's Form 4 filed on March 3, 2026, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadvertently overstated the Reporting Person's beneficial ownership by 1,987 shares. The correct number of shares beneficially owned by the Reporting Person is reflected in this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,987 | $25.70 | $51,065.90 |
DisclosureSEC source: 0001628280-26-014326 · wk-form4_1772588538.xml · nonDerivative · entry 5 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,932 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 193 | $25.91 | $5,001.38 |
DisclosureSEC source: 0001628280-26-014326 · wk-form4_1772588538.xml · nonDerivative · entry 4 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,932 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.71 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,553 | $25.16 | $164,876.10 |
DisclosureSEC source: 0001628280-26-014326 · wk-form4_1772588538.xml · nonDerivative · entry 3 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,125 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 97,000 | $0.00 Strike: $26.97 | $0.00 |
DisclosureSEC source: 0001628280-26-014326 · wk-form4_1772588538.xml · derivative · entry 6 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 97,000 shares Expires 2036-02-27 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,325 | $27.95 | $92,933.75 |
DisclosureSEC source: 0001628280-26-014326 · wk-form4_1772588538.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,678 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014326 · wk-form4_1772588538.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,003 F1 · kind: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,714 | $25.63 | $120,819.82 |
DisclosureSEC source: 0001628280-26-005582 · wk-form4_1770255345.xml · nonDerivative · entry 4 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,003 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F6 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.56 to $25.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 19,379 | $25.24 | $489,125.96 |
DisclosureSEC source: 0001628280-26-005582 · wk-form4_1770255345.xml · nonDerivative · entry 3 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,717 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.55 to $25.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,562 | $24.97 | $213,793.14 |
DisclosureSEC source: 0001628280-26-005582 · wk-form4_1770255345.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,096 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.50 to $25.42, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:35 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,983 | $25.50 | $203,553.73 |
DisclosureSEC source: 0001628280-26-005582 · wk-form4_1770255345.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,658 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,657 | $30.23 | $50,091.11 |
DisclosureSEC source: 0001798679-25-000007 · wk-form4_1764800677.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,641 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F2 · balance_after: Includes 822 shares acquired under Arcutis Biotherapeutics, Inc. Employee Stock Purchase Plan on November 30, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 23:34 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,561 | $28.50 | $44,488.50 |
DisclosureSEC source: 0001798679-25-000006 · wk-form4_1763768041.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,476 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.24 to $28.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 23:34 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 989 | $27.95 | $27,646.60 |
DisclosureSEC source: 0001798679-25-000006 · wk-form4_1763768041.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,037 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.21 to $28.21, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:23 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 43 | $25.40 | $1,092.14 |
DisclosureSEC source: 0001798679-25-000004 · wk-form4_1762385030.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,026 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.3361 to $25.40, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 23:23 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 7,165 | $24.71 | $177,063.63 |
DisclosureSEC source: 0001798679-25-000004 · wk-form4_1762385030.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,069 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.31 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 36,130 | $16.16 | $583,716.28 |
DisclosureSEC source: 0001787306-25-000134 · wk-form4_1757366076.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,234 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.93 to $16.3787, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,330 | $14.33 | $90,687.38 |
DisclosureSEC source: 0001787306-25-000116 · wk-form4_1754432921.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,364 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.965 to $14.675, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,095 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| May 28, 2025 Filed May 30, 2025 00:25 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,800 | $13.78 | $24,806.52 |
DisclosureSEC source: 0002065881-25-000011 · wk-form4_1748564737.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,599 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"), granted on January 3, 2022. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.64 to $14.16, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 02, 2025 Filed May 5, 2025 21:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,030 | $15.20 | $76,453.49 |
DisclosureSEC source: 0001787306-25-000086 · wk-form4_1746480029.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,399 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted on February 13, 2024. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.75 to $15.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,263 | $13.03 | $42,520.48 |
DisclosureSEC source: 0001787306-25-000038 · wk-form4_1741135382.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,429 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2022 and March 2, 2023. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.6902 to $13.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 89,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001787306-25-000038 · wk-form4_1741135382.xml · derivative · entry 3 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 89,000 shares Expires 2035-02-28 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000038 · wk-form4_1741135382.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,692 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,338 | $12.70 | $105,892.60 |
DisclosureSEC source: 0001787306-25-000017 · wk-form4_1738717273.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,692 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Reflects the adjusted total which includes the acquisition of 4,000 shares and 1,657 shares under the Company's Employee Stock Purchase Plan on May 31, 2024 and November 30, 2024, respectively, which transactions were exempt from Section 16(a) and (b) and were erroneously reported as non-exempt purchases in the Reporting Person's Form 4 filed on December 3, 2024. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 1,657 | $7.11 | $11,774.64 |
DisclosureSEC source: 0001787306-24-000168 · wk-form4_1733260612.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,030 F1 · shares: Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 00:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,775 | $9.68 | $17,190.34 |
DisclosureSEC source: 0001787306-24-000159 · wk-form4_1732063965.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,373 F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable tax withholdings. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.22 to $10.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 00:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000159 · wk-form4_1732063965.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,148 F1 · shares: Represents the vesting of performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was certified as satisfied on November 18, 2022. The PSUs vest 25% per year on each anniversary of the certification date, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,015 | $8.68 | $43,551.26 |
DisclosureSEC source: 0001787306-24-000145 · wk-form4_1730843178.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,273 F1 · shares: The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.32 to $8.86, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,220 | $9.02 | $47,064.04 |
DisclosureSEC source: 0001787306-24-000118 · wk-form4_1722890249.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,288 F1 · shares: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.74 to $9.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 31, 2024 Filed Dec 3, 2024 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 4,000 | $1.69 | $6,768.00 |
DisclosureSEC source: 0001787306-24-000168 · wk-form4_1733260612.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,373 F1 · shares: Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan. Read SEC document |
| May 28, 2024 Filed May 29, 2024 23:38 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,775 | $9.01 | $15,988.14 |
DisclosureSEC source: 0001787306-24-000083 · wk-form4_1717025879.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,508 F2 · kind: The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the reporting person's PSUs. F3 · price: The transaction was executed in multiple trades in prices ranging from $8.99 to $9.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 27, 2024 Filed May 29, 2024 23:38 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000083 · wk-form4_1717025879.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,283 F1 · shares: Represents performance stock units ("PSUs") initially granted on January 3, 2022 that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:22 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 5,016 | $8.74 | $43,828.80 |
DisclosureSEC source: 0001787306-24-000069 · wk-form4_1714767741.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,408 F1 · shares: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,760 | $11.12 | $41,815.71 |
DisclosureSEC source: 0001787306-24-000042 · wk-form4_1709763281.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,424 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 55,800 | Not disclosed Strike: $15.82 | Not disclosed |
DisclosureSEC source: 0001787306-24-000018 · wk-form4_1708039941.xml · derivative · entry 6 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,800 shares Expires 2033-03-02 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. F6 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 35,300 | Not disclosed Strike: $17.67 | Not disclosed |
DisclosureSEC source: 0001787306-24-000018 · wk-form4_1708039941.xml · derivative · entry 5 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F5 · derivative.exercise_date: The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (right to buy) · Derivative | 185,000 | Not disclosed Strike: $22.79 | Not disclosed |
DisclosureSEC source: 0001787306-24-000018 · wk-form4_1708039941.xml · derivative · entry 4 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,000 shares Expires 2032-01-03 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 3, 2022, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. F4 · derivative.exercise_date: The canceled option vested as to 1/4 of the total shares on January 3, 2023, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on January 3, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 27,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000018 · wk-form4_1708039941.xml · nonDerivative · entry 3 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,184 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 17,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000018 · wk-form4_1708039941.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,284 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 74,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000018 · wk-form4_1708039941.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,634 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 3, 2022, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 176,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000008 · wk-form4_1705527155.xml · derivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2034-01-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniverary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000008 · wk-form4_1705527155.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,634 F1 · shares: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annual on February 1, (the "Vesting Commencement Date"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 21, 2023 Filed Nov 21, 2023 22:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,850 | $1.98 | $3,661.15 |
DisclosureSEC source: 0001787306-23-000126 · wk-form4_1700606852.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,634 F2 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable tax withholdings. F3 · price: The transaction was executed in multiple trade in prices ranging from $1.965 to $1.98, inclusive. The price reported in Column 4 reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000126 · wk-form4_1700606852.xml · nonDerivative · entry 1 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,484 F1 · shares: Represents performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on November 18, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 1,463 | $6.38 | $9,333.94 |
DisclosureSEC source: 0001787306-23-000066 · wk-form4_1685752267.xml · nonDerivative · entry 3 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,609 F4 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,830 | $7.80 | $14,278.21 |
DisclosureSEC source: 0001787306-23-000066 · wk-form4_1685752267.xml · nonDerivative · entry 2 Matsuda Masaru · CIK 0001798679 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,146 F2 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable withholding taxes. F3 · price: The transaction was executed in multiple trades in prices ranging from $7.79 to $7.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.